The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients
Open accessAbstract
BACKGROUND: Peritoneal dissemination of abdominal malignancy (carcinomatosis) has a clinical course marked by bowel obstruction and death; it traditionally does not respond well to systemic therapy and has been approached with nihilism. To treat carcinomatosis, we use cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: A prospective database of patients has been maintained since 1992. Patients with biopsy-proven peritoneal surface disease were uniformly evaluated for, and treated with, CS and HIPEC. Patient demographics, performance status (Eastern Cooperative Oncology Group), resection status, and peritoneal surface disease were classified according to primary site. Univariate and multivariate analyses were performed. The experience was divided into quintiles and outcomes compared. RESULTS: Between 1991 and 2013, a total of 1,000 patients underwent 1,097 HIPEC procedures. Mean age was 52.9 years and 53.1% were female. Primary tumor site was appendix in 472 (47.2%), colorectal in 248 (24.8%), mesothelioma in 72 (7.2%), ovary in 69 (6.9%), gastric in 46 (4.6%), and other in 97 (9.7%). Thirty-day mortality rate was 3.8% and median hospital stay was 8 days. Median overall survival was 29.4 months, with a 5-year survival rate of 32.5%. Factors correlating with improved survival on univariate and multivariate analysis (p ≤ 0.0001 for each) were preoperative performance status, primary tumor type, resection status, and experience quintile (p = 0.04). For the 5 quintiles, the 1- and 5-year survival rates, as well as the complete cytoreduction score (R0, R1, R2a) have increased, and transfusions, stoma creations, and complications have all decreased significantly (p < .001 for all). CONCLUSIONS: This largest reported single-center experience with CS and HIPEC demonstrates that prognostic factors include primary site, performance status, completeness of resection, and institutional experience. The data show that outcomes have improved over time, with more complete cytoreduction and fewer serious complications, transfusions, and stomas. This was due to better patient selection and increased operative experience. Cytoreductive surgery with HIPEC represents a substantial improvement in outcomes compared with historical series, and shows that meaningful long-term survival is possible for selected carcinomatosis patients. Multi-institutional cooperative trials are needed to refine the use of CS and HIPEC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Verwaal, V. J., van Ruth, S., de Bree, E., van Slooten, G. W., van Tinteren, H., Boot, H., & Zoetmulder, F. A. N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.187 · Cited by 2,049
Sadeghi, B., Arvieux, C., Glehen, O., Beaujard, A. C., Rivoire, M., Baulieux, J., Fontaumard, E., Brachet, A., Caillot, J. L., Faure, J. L., et al. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o · Cited by 1,200
Glehen, O., Kwiatkowski, F., Sugarbaker, P. H., Elias, D., Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.012 · Cited by 1,184
Self-citationChua, T. C., Moran, B. J., Sugarbaker, P. H., Levine, E. A., Glehen, O., Gilly, F. N., Baratti, D., Deraco, M., Elias, D., Sardi, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7166 · Cited by 1,071
Self-citationAdvances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889
Ronnett, B. M., Zahn, C. M., Kurman, R. J., Kass, M. E., Sugarbaker, P. H., & Shmookler, B. M. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199512000-00006 · Cited by 776
Yan, T. D., Deraco, M., Baratti, D., Kusamura, S., Elias, D., Glehen, O., Gilly, F. N., Levine, E. A., Shen, P., Mohamed, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9640 · Cited by 696
Self-citationRothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Franko, J., Shi, Q., Goldman, C. D., Pockaj, B. A., Nelson, G. D., Goldberg, R. M., Pitot, H. C., Grothey, A., Alberts, S. R., & Sargent, D. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1039 · Cited by 587
Feldman, A. L., Libutti, S. K., Pingpank, J. F., Bartlett, D. L., Beresnev, T. H., Mavroukakis, S. M., Steinberg, S. M., Liewehr, D. J., Kleiner, D. E., & Alexander, H. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.150 · Cited by 350
Yan, T. D., Black, D., Savady, R., & Sugarbaker, P. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1142 · Cited by 343
Franko, J., Ibrahim, Z., Gusani, N. J., Holtzman, M. P., Bartlett, D. L., & Zeh, H. J. (2010) · Cancer · doi:10.1002/cncr.25116 · Cited by 313
Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure
Dedrick, R. L., & Flessner, M. F. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.7.480 · Cited by 305
Barlogie, B., Corry, P. M., & Drewinko, B. (1980) · PubMed · Cited by 265
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Speyer, J. L., Collins, J. M., Dedrick, R. L., Brennan, M. F., Buckpitt, A. R., Londer, H., DeVita, V. T., & Myers, C. E. (1980) · PubMed · Cited by 252
Ozols, R. F., Young, R. C., Speyer, J. L., Sugarbaker, P. H., Greene, R. F., Jenkins, J., & Myers, C. E. (1982) · PubMed · Cited by 226
Elias, D. M., Delpéro, J., Sidéris, L., Benhamou, E., Pocard, M. D., Baton, O., Giovannini, M. F., & Lasser, P. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.09.008 · Cited by 211
Levine, E. A., Stewart, J. H., Russell, G. B., Geisinger, K. R., Loggie, B. L., & Shen, P. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.12.048 · Cited by 199
Self-citationTuraga, K., Levine, E., Barone, R., Sticca, R., Petrelli, N., Lambert, L., Nash, G., Morse, M., Adbel-Misih, R., Alexander, H. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3061-z · Cited by 194
Self-citationWitkamp, A. J., de Bree, E., Kaag, M. M., van Slooten, G. W., van Coevorden, F., & Zoetmulder, F. A. N. (2001) · Journal of British Surgery · doi:10.1046/j.1365-2168.2001.01701.x · Cited by 170
Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis
McQuellon, R. P., Loggie, B. W., Fleming, R. A., Russell, G. B., Lehman, A. B., & Rambo, T. D. (2001) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.2000.1033 · Cited by 163
Self-citationDeraco, M., Baratti, D., Inglese, M. G., Allaria, B., Andreola, S., Gavazzi, C., & Kusamura, S. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.07.002 · Cited by 163
Yan, T. D., Deraco, M., Elias, D., Glehen, O., Levine, E. A., Moran, B. J., Morris, D. L., Chua, T. C., Piso, P., Sugarbaker, P. H., et al. (2011) · Cancer · doi:10.1002/cncr.25640 · Cited by 163
Self-citationMcQuellon, R. P., Loggie, B. W., Lehman, A. B., Russell, G. B., Fleming, R. A., Shen, P., & Levine, E. A. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.03.067 · Cited by 156
Self-citationTreatment of Primary Peritoneal Mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP)
Park, B. J., Alexander, H. R., Libutti, S. K., Wu, P., Royalty, D., Kranda, K. C., & Bartlett, D. L. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0582-6 · Cited by 156
Jacquet, P., Averbach, A. M., Stuart, O. A., Chang, D. W.-W., & Sugarbaker, P. H. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050721 · Cited by 148
Markman, M., Brady, M. F., Spirtos, N. M., Hanjani, P., & Rubin, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2620 · Cited by 143
Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors
Hendren, S. K., Hahn, S. M., Spitz, F. R., Bauer, T. W., Rubin, S. C., Zhu, T. C., GLATSTEIN, E. J., & Fraker, D. L. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0065-x · Cited by 122
Taguchi, T. (1995) · PubMed · Cited by 117
Nuclear matrix as a target for hyperthermic killing of cancer cells
Roti, J. L. R., Kampinga, H. H., Malyapa, R. S., Wright, W. D., Vanderwaal, R. P., & Xu, M. (1998) · Cell Stress and Chaperones · doi:10.1054/csac.1998.0103 · Cited by 105
Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in Two Distinct Databases
Hoverman, J. R., Cartwright, T. H., Patt, D. A., Espirito, J. L., Clayton, M. P., Garey, J. S., Kopp, T. J., Kolodziej, M. A., Neubauer, M., Fitch, K., et al. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000318 · Cited by 103
Levine, E. A., Blazer, D. G., Kim, M. K., et al. (2012) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.12.028 · Cited by 94
Self-citationInterspecies Scaling of Regional Drug Delivery
Dedrick, R. L. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751106 · Cited by 92
Bartlett, D. L., Buell, J. F., Libutti, S. K., Reed, E., Lee, K. B., Figg, W. D., Venzon, D. J., & Alexander, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1251::aid-cncr27>3.0.co;2-3 · Cited by 81
Prognostic Significance of Histomorphologic Parameters in Diffuse Malignant Peritoneal Mesothelioma
Cerruto, C. A., Brun, E. A., Chang, D., & Sugarbaker, P. H. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-1654-psohpi · Cited by 78
Ihemelandu, C. U., McQuellon, R. P., Shen, P., Stewart, J. H., Votanopoulos, K. I., & Levine, E. A. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3049-8 · Cited by 74
Self-citationBlackham, A. U., Shen, P., Stewart, J. H., Russell, G. B., & Levine, E. A. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1080-6 · Cited by 73
Self-citationPharmacokinetic Characteristics of 5-Fluorouracil and Mitomycin C in Intraperitoneal Chemotherapy
Kuzuya, T., Yamauchi, M., Ito, A., Hasegawa, M., Hasegawa, T., & Nabeshima, T. (1994) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1994.tb03883.x · Cited by 62
Intraperitoneal Chemotherapy Comes of Age
Cannistra, S. A. (2006) · New England Journal of Medicine · doi:10.1056/nejme058308 · Cited by 56
Lawrence, D., Maschio, M., Leahy, K. J., Yunger, S., Easaw, J. C., & Weinstein, M. C. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.852097 · Cited by 39
Duckworth, K. E., McQuellon, R. P., Russell, G. B., Cashwell, C. S., Shen, P., Stewart, J. H., & Levine, E. A. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23089 · Cited by 32
Self-citation
Cited by
Quénet, F., Elias, D., Roca, L., Goéré, D., Ghouti, L., Pocard, M., Facy, O., Arvieux, C., Lorimier, G., Pezet, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30599-4 · Cited by 827
Advances in Chitosan-Based Smart Hydrogels for Colorectal Cancer Treatment
Piotrowska, U., & Orzechowska, K. (2024) · Pharmaceuticals · doi:10.3390/ph17101260 · Cited by 30
Metadata
- Authors
- Levine, E. A., Stewart, J. H., Shen, P., Russell, G. B., Loggie, B. L., & Votanopoulos, K. I.
- Venue
- Journal of the American College of Surgeons
- Published
- 2014-04
- Volume
- 218
- Issue
- 4
- Pages
- 573-585
- ISSN
- 1072-7515 (ISSN-L)
- OpenAlex
- W2073581648
- Cited by
- 270
- References
- 45
- FWCI
- 19.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.